Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Seres Therapeutics Inc
MCRBCurrent price
7.67 USD
+0.33 USD (+4.50%)
Last closed
7.44 USD
Company
www.serestherapeutics.com
ISIN
US81750R1023
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
64 969 204 USD
Yield for 12 month
+725.17 %
1Y
3Y
5Y
10Y
15Y
MCRB
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Address: 101 Cambridgepark Drive, Cambridge, MA, United States, 02140
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
13.33 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+126 325 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-3 532 000 USD
Last Year
+125 621 000 USD
Current Quarter
-3 527 000 USD
Last Quarter
–
Key Figures MCRB
1 year
3 years
5 years
10 years
EBITDA
-109 128 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-28.22 %
PEG Ratio
-0.11
Return On Equity TTM
-1 556.28 %
Wall Street Target Price
13.33 USD
Revenue TTM
126 325 000 USD
Book Value
5.78 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-93.40 %
Dividend Yield
–
Gross Profit TTM
-18 055 000 USD
Earnings per share
-7.95 USD
Diluted Eps TTM
-7.95 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics MCRB
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History MCRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:20
Payout Ratio TTM
–
Last Split Date
22.04.2025
Stock Valuation MCRB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
3.96
Enterprise Value Revenue
805.87
Price Sales TTM
390.27
Enterprise Value EBITDA
-2.07
Price Book MRQ
1.29
Financials MCRB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators MCRB
For 52 weeks
6.53 USD
30.60 USD
50 Day MA
10.71 USD
Shares Short Prior Month
15 262 138
200 Day MA
15.28 USD
Short Ratio
4.80
Shares Short
610 359
Short Percent
11.38 %
BeatStart